Comparison
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870 vs 4 Hydroxyphenylpyruvic Aciduria C1848678
Clinical comparison between 46 XY Disorder OF Sex Development Due TO Impaired Androgen Production and 4 Hydroxyphenylpyruvic Aciduria for differential diagnosis and treatment planning.
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
A disorder where androgen production is impaired in 46,XY individuals. Results in undervirilization and atypical genital development. Treated with hormone replacement and supportive care.
4 Hydroxyphenylpyruvic Aciduria C1848678
A metabolic disorder involving difficulty processing tyrosine, an amino acid. Can affect development and growth. Treatment focuses on dietary management and supportive care.
6 comparison axes
Onset
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
0-0
4 Hydroxyphenylpyruvic Aciduria C1848678
0-5
Onset patterns differ
Severity
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
severe
4 Hydroxyphenylpyruvic Aciduria C1848678
moderate
Different severity levels
Chronic
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
Chronic
4 Hydroxyphenylpyruvic Aciduria C1848678
Chronic
Differing course
Communicable
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
No
4 Hydroxyphenylpyruvic Aciduria C1848678
No
Different transmission
Body System
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
reproductive
4 Hydroxyphenylpyruvic Aciduria C1848678
metabolic
Same/different system
Category
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
endocrine
4 Hydroxyphenylpyruvic Aciduria C1848678
metabolic
Different category
Bottom line
46-xy-disorder-of-sex-development-due-to-impaired-androgen-production-C5679870 and 4-hydroxyphenylpyruvic-aciduria-C1848678 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870 | 4 Hydroxyphenylpyruvic Aciduria C1848678 | Discriminating power |
|---|---|---|---|
| Genital development | May cause undervirilization or atypical genitalia in a 46,XY person. | Not described as a primary disorder of genital development. | High |
| Metabolic features | Androgen production is the core problem, not tyrosine processing. | Suggests impaired tyrosine metabolism and possible growth or developmental effects. | Moderate |
| Recognition timing | Often considered at birth when genital appearance is atypical. | Source range is early childhood, but timing alone is not diagnostic. | Moderate |
When to favor each condition
Choose 46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870 when
46,XY infant with undervirilization
This pattern fits an androgen-production disorder pending specialist confirmation.
Moderate
Endocrine evaluation of atypical genitalia
The supplied category is reproductive and endocrine rather than metabolic.
High
Hormone testing suggests reduced androgen effect
Supports this category, but the exact cause still needs confirmation.
Moderate
Choose 4 Hydroxyphenylpyruvic Aciduria C1848678 when
Urine contains 4-hydroxyphenylpyruvate
This identifies a biochemical finding, not a complete diagnosis by itself.
High
Tyrosine-metabolism concern with growth issues
The source links the finding to possible effects on growth and development.
Moderate
Metabolic abnormality without genital undervirilization
This points away from an androgen-production disorder of sex development.
Moderate
How key tests differ
| Test | 46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870 | 4 Hydroxyphenylpyruvic Aciduria C1848678 | Interpretation |
|---|---|---|---|
| Karyotype | 46,XY is part of the concept definition. | Karyotype does not establish the finding. | Chromosomes provide context for the left concept only. |
| Androgen and endocrine studies | May indicate impaired androgen production or effect; no cutoff is supplied. | Not the primary defining test. | Abnormal results need endocrine confirmation and are not definitive alone. |
| Urine organic acids | Not expected to define the condition. | May show 4-hydroxyphenylpyruvic acid. | An elevated metabolite requires correlation and further metabolic testing. |
Prognosis comparison
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
- Outcome
- A chronic endocrine condition whose individual outcome is not quantified here.
- Factors
- Specific cause, degree of undervirilization, and timing of specialist care.
4 Hydroxyphenylpyruvic Aciduria C1848678
- Outcome
- A chronic metabolic finding or disorder whose course is not established here.
- Factors
- Underlying cause, response to dietary care, and growth or development.
Time frame: From infancy or early childhood through ongoing follow-up.
Accurate diagnosis, monitoring, supportive treatment, and associated conditions.
Complications comparison
| Complication | Presentation |
|---|---|
| Sex development and fertility | Undervirilization and later reproductive implications may occur; outcomes vary. Not described as a typical feature. Fertility cannot be predicted from these limited data. |
| Growth and development | Not the core complication described in the source. Growth or development may be affected, but severity is not established. Monitoring should be individualized by specialists. |
| Ongoing care needs | May include hormone replacement and psychosocial support. May include dietary management and supportive care. No treatment dose or regimen is established here. |
Patient education highlights
- HighDifferent conditions
One concerns androgen production in 46,XY development; the other concerns tyrosine-related metabolites.
- HighResults need interpretation
An abnormal hormone or urine result is not automatically a final diagnosis.
- MediumSpecialist follow-up
Endocrine or metabolic clinicians guide testing, monitoring, and supportive treatment.